Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2022 Oct 25:2022.10.24.513619.
doi: 10.1101/2022.10.24.513619.

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters

Ai-Ris Y Collier  1 , Jessica Miller  1 , Nicole P Hachmann  1 , Katherine McMahan  1 , Jinyan Liu  1 , Esther Apraku Bondzie  1 , Lydia Gallup  1 , Marjorie Rowe  1 , Eleanor Schonberg  1 , Siline Thai  1 , Julia Barrett  1 , Erica N Borducchi  1 , Emily Bouffard  1 , Catherine Jacob-Dolan  1 , Camille R Mazurek  1 , Audrey Mutoni  1 , Olivia Powers  1 , Michaela Sciacca  1 , Nehalee Surve  1 , Haley VanWyk  1 , Cindy Wu  1 , Dan H Barouch  1
Affiliations

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters

Ai-Ris Y Collier et al. bioRxiv. .

Update in

  • Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
    Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, Barrett J, Borducchi EN, Bouffard E, Jacob-Dolan C, Mazurek CR, Mutoni A, Powers O, Sciacca M, Surve N, VanWyk H, Wu C, Barouch DH. Collier AY, et al. N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11. N Engl J Med. 2023. PMID: 36630611 Free PMC article. No abstract available.

Abstract

Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.. Neutralizing antibody and T cell responses following monovalent and bivalent mRNA boosting.
A, B. Neutralizing antibody (NAb) titers by luciferase-based pseudovirus neutralization assays in individuals following monovalent or bivalent mRNA boosting. C, D. Spike-specific CD8+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. E, F. Spike-specific CD4+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. Responses were measured against the SARS-CoV-2 WA1/2020, Omicron BA.1, BA.2, and BA.5 variants. Medians (red bars) are depicted and shown numerically with fold differences.
Figure 1.
Figure 1.. Neutralizing antibody and T cell responses following monovalent and bivalent mRNA boosting.
A, B. Neutralizing antibody (NAb) titers by luciferase-based pseudovirus neutralization assays in individuals following monovalent or bivalent mRNA boosting. C, D. Spike-specific CD8+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. E, F. Spike-specific CD4+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. Responses were measured against the SARS-CoV-2 WA1/2020, Omicron BA.1, BA.2, and BA.5 variants. Medians (red bars) are depicted and shown numerically with fold differences.
Figure 1.
Figure 1.. Neutralizing antibody and T cell responses following monovalent and bivalent mRNA boosting.
A, B. Neutralizing antibody (NAb) titers by luciferase-based pseudovirus neutralization assays in individuals following monovalent or bivalent mRNA boosting. C, D. Spike-specific CD8+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. E, F. Spike-specific CD4+ T cell responses by intracellular cytokine staining assays in individuals following monovalent or bivalent mRNA boosting. Responses were measured against the SARS-CoV-2 WA1/2020, Omicron BA.1, BA.2, and BA.5 variants. Medians (red bars) are depicted and shown numerically with fold differences.
See this image and copyright information in PMC

References

    1. Lin DY, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA 2022;328:1415–26. - PMC - PubMed
    1. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. N Engl J Med 2022;387:1332–3. - PMC - PubMed
    1. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86–8. - PMC - PubMed
    1. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med 2022;387:1279–91. - PMC - PubMed
    1. Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 2022;377:eabq1841. - PMC - PubMed

Publication types